Roche
Produtos Roche Químicos e Farmacêuticos S.A. operates Roche's Brazilian pharmaceutical operations, supplying oncology, neuroscience, rare-disease, ophthalmology, and immunology medicines alongside Accu-Chek diabetes care products and diagnostic solutions to hospitals, pharmacies, healthcare professionals, and public-sector buyers in Brazil.
- Company typePublic
- Founded1896
- HeadquartersSão Paulo, Brazil
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Roche does
Produtos Roche Químicos e Farmacêuticos S.A. is the Brazilian operating entity of the Swiss-headquartered Roche Group, headquartered at Av. Engenheiro Billings, 1729 in São Paulo, with a separate corporate office at Rua Dr. Rubens Gomes Bueno, 691 in Várzea de Baixo. The company runs three core businesses in Brazil through wholly-owned subsidiaries: Roche Farma Brasil (pharmaceuticals), Roche Diagnóstica Brasil (in-vitro diagnostics), and Roche Diabetes Care Brasil (Accu-Chek). Its pharmaceutical portfolio spans oncology, immuno-oncology, neuroscience, rare diseases (including spinal muscular atrophy via Evrysdi and hemophilia A via Hemcibra), and ophthalmology (Vabysmo), with named brands such as Actemra, Alecensa, Avastin, Ocrevus, Herceptin, Tecentriq, Enspryng, and Phesgo. Roche serves healthcare professionals, healthcare institutions (hospitals, clinics, laboratories), and patients, addressing unmet needs across multiple therapeutic areas with a stated pipeline of 110+ complex molecules under development.
The technology backbone combines pharmaceutical R&D with diagnostic capabilities under a personalized-medicine strategy, complemented by the Accu-Chek diabetes care franchise. The most technically differentiated asset is the Accu-Chek SmartGuide AI-enabled continuous glucose monitoring (CGM) solution, which received CE Mark approval in July 2024 for adults with type 1 and type 2 diabetes on flexible insulin therapy; its predictive algorithms forecast hypoglycemia risk within 30 minutes, predict glucose levels over two hours, estimate nocturnal hypoglycemia risk, and demonstrated 9.2% MARD accuracy. AI is also applied to pathology diagnostics (anomaly detection, treatment planning, drug discovery) and to real-world data initiatives such as the Roche Farma RWD Latam Initiative. Sub-brands such as Roche Dialogo (medical-scientific portal), Portal de Pacientes, Mulher Consciente, Visionaries, and Conexão Roche extend the platform into HCP and patient engagement.
Roche's revenue model is sales-led and B2B, operating through four channels: direct sales to hospitals and clinics, pharmacy and licensed distributor networks, public procurement (licitações) with dedicated bid management, and inside-sales direct customer service for Accu-Chek via 0800 772 0126. Pharmaceutical pricing in Brazil is regulated by CMED (Câmara de Medicamentos do Ministério da Saúde), and Roche sells only to legal entities (pharmacies, hospitals, distributors), not directly to patients. Distribution is supported by 0800 medical information, pharmacovigilance, and customer service lines, plus dedicated HCP and patient portals. The company has no parent within the provided Brazil-specific data and is the local representation of the globally listed Roche Holding AG (SIX: ROG).
Roche firmographics
Firmographics- Name
- Roche
- Legal name
- Produtos Roche Químicos e Farmacêuticos S.A.
- Website
- https://roche.com.br
- Company type
- Public
- Founded year
- 1896
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Produtos Roche Químicos e Farmacêuticos S.A. operates Roche's Brazilian pharmaceutical operations, supplying oncology, neuroscience, rare-disease, ophthalmology, and immunology medicines alongside Accu-Chek diabetes care products and diagnostic solutions to hospitals, pharmacies, healthcare professionals, and public-sector buyers in Brazil.
- Ownership category
- akta.pro rank
Roche industry classification
Industry- Product category
- Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Surgical Appliance and Supplies Manufacturing (339113), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)
Keywords
Where Roche is headquartered
LocationHeadquarters
- HQ city
- São Paulo
- HQ country
- Brazil
- HQ region
- Latin America
Offices2 records
Markets served
Roche business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- Pharmaceutical Products: Roche develops and sells innovative medicines for unmet medical needs in oncology, immuno-oncology, neuroscience, rare diseases, and ophthalmology. Revenue generated through direct sales to hospitals, clinics, pharmacies, and distributors, as well as public procurement (licitações).
- Diagnostic Products: Roche Diagnóstica provides diagnostic solutions and testing products. Revenue generated through sales to healthcare institutions, laboratories, and direct customer service channels.
- Diabetes Care Products: Roche Diabetes Care offers blood glucose monitoring products under the Accu-Chek brand. Revenue from sales of monitoring devices and consumables through pharmacies, direct customer service, and distributors.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Pharmaceutical products sold through pharmacies and hospitals |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
Roche product offering
Product offeringCore offering
Roche develops and supplies innovative pharmaceutical medicines for oncology, immuno-oncology, neuroscience, rare diseases, and ophthalmology, alongside in-vitro diagnostic testing products and Accu-Chek diabetes care solutions. The company combines pharmaceutical and diagnostic capabilities to deliver personalized healthcare, selling through hospitals, clinics, pharmacies, distributors, and public procurement channels in Brazil.
Product overview
Roche operates as an integrated healthcare company offering pharmaceutical products and medical diagnostics. The pharmaceutical division provides innovative medications across oncology, immunology, neuroscience, rare diseases, and ophthalmology, including key products like Avastin, Herceptin, Tecentriq, Ocrevus, and Vabysmo. The diabetes care division focuses on the Accu-Chek brand of blood glucose monitoring products, including the recently launched Accu-Chek SmartGuide AI-enabled CGM solution. The diagnostics division provides laboratory and point-of-care diagnostic solutions. Roche's portfolio emphasizes personalized medicine, combining pharmaceutical and diagnostic capabilities.
Differentiator
Problem solved
Functional benefit
Brands
- Accu-Chek: Blood glucose monitoring devices and diabetes care solutions
- Roche Dialogo
- Conexão Roche
- Mulher Consciente
- Visionaries
Products and services
- Actemra (tocilizumabe) Monoclonal antibody medication indicated for autoimmune diseases, prescribed by physicians and dispensed through pharmacies and hospitals.
- Alecensa (cloridrato de alectinibe) Tyrosine kinase inhibitor indicated for ALK-positive non-small cell lung cancer, sold to hospitals and oncology specialists.
- Avastin (bevacizumabe) Anti-angiogenic therapy indicated for various cancers including colorectal, lung, and breast cancer.
- Ocrevus (ocrelizumabe) Monoclonal antibody indicated for multiple sclerosis and neuromyelitis optica spectrum disorder, sold to neurology specialists and hospitals.
- Hemcibra (emicizumabe) Bispecific monoclonal antibody indicated for hemophilia A, sold to hematology specialists and hospitals.
- Herceptin (trastuzumabe) Monoclonal antibody indicated for HER2-positive breast cancer and gastric cancer, sold to oncology specialists and hospitals. Discontinuation of 150 mg IV importation to Brazil notified on 2026-02-10 due to lack of market demand.
- Tecentriq (atezolizumabe) PD-L1 inhibitor indicated for various cancers including lung, bladder, and breast cancer.
- Vabysmo (faricimabe) Bispecific antibody indicated for ophthalmology conditions including neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
- Evrysdi (risdiplam) SMN2 splicing modifier indicated for spinal muscular atrophy.
- Enspryng (satralizumabe) Monoclonal antibody indicated for neuromyelitis optica spectrum disorder (NMOSD).
- Phesgo (pertuzumabe + trastuzumabe) Fixed-dose combination indicated for HER2-positive breast cancer.
- Accu-Chek SmartGuide AI-enabled continuous glucose monitoring solution with predictive hypoglycemia algorithms for adults with type 1 and type 2 diabetes on flexible insulin therapy.
- Accu-Chek Blood Glucose Monitoring Products Blood glucose monitoring devices and consumables sold under the Accu-Chek brand through pharmacies, distributors, and direct customer service for people with diabetes.
- Roche Diagnostic Solutions In-vitro diagnostic tests, reagents, and laboratory/point-of-care diagnostic solutions supplied to laboratories, hospitals, and healthcare institutions.
Quantifiable outcome
- 9.2% MARD accuracy for Accu-Chek SmartGuide CGM solution
- +2 more outcomes
Companies that use Roche
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles4 records
Roche technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature2 records
Roche partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- INAME (Instituto Nacional de Atrofia Muscular Espinhal)corePartnership with INAME for 'Um Olhar sobre a AME tipo III no Brasil' research initiative conducted by VEJA SAÚDE with Roche support, collecting data from over 120 participants.
- IQVIA LtdcoreIQVIA Ltd provides IT support, maintenance, and business continuity services for Roche's technology infrastructure. Located at 210 Pentonville Road, London N1 9JY, England, UK.
- The Valuable 500minorRoche made a public commitment to The Valuable 500, an organization with the mission to use the power of business to promote lasting change for 1.3 billion people worldwide living with disabilities.
- Instituto OncoguiacorePartnership with Instituto Oncoguia to produce video series addressing the role of patient associations in cancer patient journeys. Content covers access to associations, welcoming and support networks, treatment quality, and patient rights.
- Femama (Federação Brasileira de Instituições Filantrópicas de Apoio à Saúde da Mama)corePartnership in the 'Um Olhar Sobre o Câncer de Mama no Brasil' research initiative, conducted by Editora Abril with Roche support, surveying 1,237 breast cancer patients.
- PEV Consultoria em SaúdeminorRoche Farma partnered with PEV Consultoria em Saúde to develop an e-book on real-world health data in Latin America, coordinating with health technology assessment specialists.
- Retina BrasilminorPartnership with Retina Brasil and FGV CPDOC for research on patient perception of AMD and diabetic macular edema, supported by Roche Brasil.
- INAME (Instituto Nacional de Atrofia Muscular Espinhal)corePartnership for 'Retrato da AME no Brasil' research initiative, a quantitative study conducted with 144 respondents including people with SMA and caregivers.
- Grupo Mulheres do Brasil and eCycleminorSupport for the '#NaoUsouDescartou' initiative to help find medication disposal locations, supported by Grupo Mulheres do Brasil and eCycle.
Scale indicators6 records
Recent moves5 records
Expansion highlights4 records
Roche competitors and assessment
Company assessmentBroad incumbents
- Johnson & Johnson (Innovative Medicine): Major oncology and immunology pharma peer (Darzalex, Tremfya, Erleada) with comparable scale and similar GTM motion targeting specialists and hospitals.
- Pfizer: Global pharma major with significant oncology and rare-disease franchises (Seagen). Comparable scale, broad therapeutic-area coverage, and similar GTM motion via hospitals and physician channels.
- AstraZeneca: Global pharma peer with major oncology (Tagrisso, Imfinzi, Enhertu) and rare-disease franchises. Competes directly with Roche in lung cancer and other oncology indications.
- Sanofi: Global pharma peer with overlapping immunology (Dupixent), rare disease, and oncology franchises. Comparable scale and breadth, including diabetes care historically.
- Novartis: Global pharmaceutical peer with overlapping oncology, neuroscience, and immunology portfolios. Novartis operates at similar scale with comparable therapeutic-area breadth and is a direct competitor in multiple indications.
- Eli Lilly: Major pharma peer with oncology, neuroscience, and diabetes (Mounjaro) franchises. Increasingly direct competition in diabetes and immunology as Lilly expands in endocrinology.
- Merck & Co. (MSD): Direct competitor in oncology (Keytruda competes with Tecentriq), with a similarly broad pharmaceutical portfolio. Comparable scale and pipeline depth in immuno-oncology.
- Abbott: Direct competitor in diabetes care (FreeStyle Libre CGM) and diagnostics. Operates the dominant CGM franchise globally, putting pressure on Roche's Accu-Chek SmartGuide launch.
Regional players
- Bio-Rad Laboratories: Diagnostics peer with overlapping clinical-diagnostics product lines. Smaller scale than Roche Diagnostics but competes in similar hospital and laboratory channels.
Direct peers
- Dexcom: CGM specialist and the leading competitor in the continuous glucose monitoring category. Directly competes with Accu-Chek SmartGuide for the same patient and prescriber base in diabetes management.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Roche social profiles
Digital presenceRoche financial estimates
Financial estimateRevenue estimate
Valuation estimate
Roche leadership team
Management profileNumber of profiles
Profiles2 records
Roche subsidiaries and ownership
Company hierarchySubsidiaries3 records
Roche funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Roche M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Roche
What does Roche do?
Roche develops and supplies innovative pharmaceutical medicines for oncology, immuno-oncology, neuroscience, rare diseases, and ophthalmology, alongside in-vitro diagnostic testing products and Accu-Chek diabetes care solutions. The company combines pharmaceutical and diagnostic capabilities to deliver personalized healthcare, selling through hospitals, clinics, pharmacies, distributors, and public procurement channels in Brazil.
Is Roche a public or private company?
Roche is a public company. It is classified as public and is currently operating.
When was Roche founded?
Roche was founded in 1896. It employs 1 to 10 people.
Where is Roche based?
Roche is headquartered in São Paulo, Brazil, in the Latin America region.
How does Roche make money?
Three revenue lines are on record. Pharmaceutical Products are the primary driver. The others are diagnostic Products and diabetes Care Products.
Who are Roche's main competitors?
Broad incumbents on record are Johnson & Johnson (Innovative Medicine), Pfizer, AstraZeneca, Sanofi, Novartis, Eli Lilly, Merck & Co. (MSD) and Abbott. Bio-Rad Laboratories is listed as a regional player. Dexcom is listed as a direct peer.
Does Roche have an API?
No public API is recorded for Roche.
What industry is Roche in?
Roche's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.